Neumora Therapeutics Inc
NMRA2.560USD
-0.020-0.78%
收盤 11/07, 16:00（美東）報價延遲15分鐘
414.07M總市值
虧損本益比TTM
關於 Neumora Therapeutics Inc 公司
Neumora Therapeutics Inc. 是一家臨牀階段的生物製藥公司。該公司的治療產品線包括七個臨牀和臨牀前神經科學項目，旨在爲廣泛的未得到充分治療的神經精神疾病和神經退行性疾病提供新的治療機制。其先進的候選產品 navacaprant (NMRA-140) 是一種新型的每日一次口服 kappa 阿片受體 (KOR) 拮抗劑，正在開發用於治療抑鬱症 (MDD)。其其他候選藥物包括 NMRA-266、NMRA-511 和 NMRA-NMDA。NMRA-266 是 M4 毒蕈鹼受體 (M4R) 的正變構調節劑程序，用於治療精神分裂症。NMRA-266 旨在選擇性地針對毒蕈鹼受體家族的 M4 受體亞型。 NMRA-511 是一種在研的加壓素 1a 受體 (V1aR) 拮抗劑。NMRA-NMDA 是一種 NMDA 正向變構調節劑方案，該公司正在開發該方案用於治療精神分裂症。
Neumora Therapeutics Inc簡介
公司代碼NMRA
公司名稱Neumora Therapeutics Inc
上市日期Sep 15, 2023
CEOMr. Paul L. Berns
員工數量110
證券類型Ordinary Share
年結日Sep 15
公司地址490 Arsenal Way
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02472
電話18577600900
網址https://neumoratx.com/
公司代碼NMRA
上市日期Sep 15, 2023
CEOMr. Paul L. Berns
Neumora Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
+72.78%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Jason G. Duncan
Mr. Jason G. Duncan
Chief Legal and Administrative Officer
Chief Legal and Administrative Officer
--
--
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
+72.78%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 10月2日 週四
更新時間: 10月2日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Amgen Inc
21.84%
ARCH Venture Partners
20.90%
Berns (Paul L)
4.74%
SB Global Advisers Ltd
4.04%
Invus Public Equities Advisors, LLC
2.69%
其他
45.79%
持股股東
持股股東
佔比
Amgen Inc
21.84%
ARCH Venture Partners
20.90%
Berns (Paul L)
4.74%
SB Global Advisers Ltd
4.04%
Invus Public Equities Advisors, LLC
2.69%
其他
45.79%
股東類型
持股股東
佔比
Venture Capital
22.04%
Corporation
21.84%
Investment Advisor
21.62%
Individual Investor
5.65%
Hedge Fund
5.33%
Investment Advisor/Hedge Fund
3.10%
Endowment Fund
2.04%
Research Firm
0.70%
Family Office
0.05%
其他
17.61%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
293
86.79M
53.64%
-40.47M
2025Q2
288
142.02M
87.70%
-25.57M
2025Q1
283
144.00M
90.43%
+12.16M
2024Q4
249
161.18M
99.54%
+45.20M
2024Q3
201
148.65M
93.66%
+40.67M
2024Q2
179
142.61M
90.03%
+47.65M
2024Q1
154
133.89M
85.01%
+50.39M
2023Q4
108
122.49M
78.90%
+50.97M
2023Q3
54
110.63M
71.42%
+110.63M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Amgen Inc
35.37M
21.84%
--
--
Apr 10, 2025
ARCH Venture Partners
31.93M
19.72%
--
--
Nov 12, 2024
Berns (Paul L)
7.68M
4.74%
+242.77K
+3.27%
Apr 10, 2025
SB Global Advisers Ltd
6.54M
4.04%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
4.36M
2.69%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
4.76M
2.94%
-562.13K
-10.56%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.50M
2.16%
+6.35K
+0.18%
Jun 30, 2025
Wellcome Trust
3.31M
2.04%
--
--
Jun 30, 2025
ICONIQ Capital, LLC
2.56M
1.58%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.55M
1.58%
-3.09M
-54.78%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Biotechnology ETF
0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Schwab U.S. Broad Market ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
iShares US Small-Cap Equity Factor ETF
佔比0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0%
Fidelity MSCI Health Care Index ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
